HRP20191513T1 - Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja - Google Patents
Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja Download PDFInfo
- Publication number
- HRP20191513T1 HRP20191513T1 HRP20191513T HRP20191513T1 HR P20191513 T1 HRP20191513 T1 HR P20191513T1 HR P20191513 T HRP20191513 T HR P20191513T HR P20191513 T1 HRP20191513 T1 HR P20191513T1
- Authority
- HR
- Croatia
- Prior art keywords
- unsubstituted
- substituted
- carboaryl
- aliphatic
- independently selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94500607P | 2007-06-19 | 2007-06-19 | |
| PCT/GB2008/002066 WO2008155533A2 (en) | 2007-06-19 | 2008-06-17 | Phenothiazine compounds for treating mild cognitive impairment |
| EP08762390.6A EP2167095B1 (en) | 2007-06-19 | 2008-06-17 | Phenothiazine compounds for treating mild cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191513T1 true HRP20191513T1 (hr) | 2019-11-29 |
Family
ID=39943003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191513 HRP20191513T1 (hr) | 2007-06-19 | 2008-06-17 | Fenotiazinski spojevi za liječenje blagog kognitivnog poremećaja |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9211294B2 (enExample) |
| EP (1) | EP2167095B1 (enExample) |
| JP (1) | JP5725605B2 (enExample) |
| CN (1) | CN101820884B (enExample) |
| AU (1) | AU2008265045B2 (enExample) |
| BR (1) | BRPI0813670A2 (enExample) |
| CA (1) | CA2690746C (enExample) |
| DK (1) | DK2167095T3 (enExample) |
| ES (1) | ES2739546T3 (enExample) |
| HR (1) | HRP20191513T1 (enExample) |
| HU (1) | HUE045460T2 (enExample) |
| MY (1) | MY177001A (enExample) |
| PL (1) | PL2167095T3 (enExample) |
| PT (1) | PT2167095T (enExample) |
| SI (1) | SI2167095T1 (enExample) |
| WO (1) | WO2008155533A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104606199B (zh) | 2006-03-29 | 2022-09-13 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| DK2205245T3 (en) * | 2007-10-03 | 2015-09-28 | Wista Lab Ltd | Therapeutic use of diaminophenothiaziner |
| JP5868955B2 (ja) | 2010-04-30 | 2016-02-24 | プロセッタ アンチバイラル インコーポレイテッド | 抗ウイルス化合物 |
| CA2827027C (en) | 2011-02-11 | 2019-06-04 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
| EP2699241B1 (en) | 2011-04-20 | 2016-07-27 | Prosetta Antiviral Inc. | Antiviral compounds |
| EP3686181B1 (en) * | 2013-01-30 | 2024-07-17 | Ecolab USA Inc. | Hydrogen sulfide scavengers |
| US10304006B2 (en) * | 2013-02-15 | 2019-05-28 | The Charles Stark Draper Laboratory, Inc. | Method for integrating and fusing heterogeneous data types to perform predictive analysis |
| DK3258938T3 (da) * | 2015-02-17 | 2021-02-01 | Univ Arizona State | Phenothiazinanaloger som mitokondrie terapeutiske midler |
| PT3487505T (pt) | 2016-07-25 | 2023-06-07 | Wista Lab Ltd | Administração e dosagem de diaminofenotiazinas |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| JP7465861B2 (ja) | 2018-07-26 | 2024-04-11 | ウィスタ ラボラトリーズ リミテッド | 集団におけるジアミノフェノチアジンの最適化投与 |
| MY209608A (en) * | 2019-04-10 | 2025-07-24 | Genting Taurx Diagnostic Centre Sdn Bhd | Adaptive neurological testing method |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| KR20250154422A (ko) | 2023-03-03 | 2025-10-28 | 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 | 미세혈관 뇌질환 치료를 위한 디아미노페노티아진 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| US20070037848A1 (en) * | 2003-04-03 | 2007-02-15 | Masters Colin L | Treatment of neurological conditions |
| JP5186212B2 (ja) * | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| ES2409683T3 (es) * | 2004-09-23 | 2013-06-27 | Wista Laboratories Ltd. | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
| WO2006091728A2 (en) * | 2005-02-24 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Microtubule stabilizing compounds and methods of their use |
| CN104606199B (zh) | 2006-03-29 | 2022-09-13 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| DK2001556T3 (da) * | 2006-03-29 | 2014-11-10 | Wista Lab Ltd | Thioninium-forbindelser og anvendelse deraf |
| DK2004155T3 (en) | 2006-03-29 | 2018-04-30 | Wista Lab Ltd | PROTEIN AGGREGATION INHIBITORS |
| CN101511803B (zh) * | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
-
2008
- 2008-06-17 PL PL08762390T patent/PL2167095T3/pl unknown
- 2008-06-17 CA CA2690746A patent/CA2690746C/en active Active
- 2008-06-17 PT PT08762390T patent/PT2167095T/pt unknown
- 2008-06-17 MY MYPI20095255A patent/MY177001A/en unknown
- 2008-06-17 DK DK08762390.6T patent/DK2167095T3/da active
- 2008-06-17 WO PCT/GB2008/002066 patent/WO2008155533A2/en not_active Ceased
- 2008-06-17 US US12/665,608 patent/US9211294B2/en active Active
- 2008-06-17 ES ES08762390T patent/ES2739546T3/es active Active
- 2008-06-17 BR BRPI0813670-0A2A patent/BRPI0813670A2/pt not_active Application Discontinuation
- 2008-06-17 HU HUE08762390A patent/HUE045460T2/hu unknown
- 2008-06-17 JP JP2010512761A patent/JP5725605B2/ja active Active
- 2008-06-17 AU AU2008265045A patent/AU2008265045B2/en active Active
- 2008-06-17 CN CN2008801031955A patent/CN101820884B/zh active Active
- 2008-06-17 HR HRP20191513 patent/HRP20191513T1/hr unknown
- 2008-06-17 EP EP08762390.6A patent/EP2167095B1/en active Active
- 2008-06-17 SI SI200832080T patent/SI2167095T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100184752A1 (en) | 2010-07-22 |
| ES2739546T3 (es) | 2020-01-31 |
| HUE045460T2 (hu) | 2019-12-30 |
| CA2690746A1 (en) | 2008-12-24 |
| MY177001A (en) | 2020-09-01 |
| WO2008155533A3 (en) | 2009-02-19 |
| PT2167095T (pt) | 2019-08-06 |
| US9211294B2 (en) | 2015-12-15 |
| CN101820884A (zh) | 2010-09-01 |
| AU2008265045B2 (en) | 2014-02-27 |
| EP2167095A2 (en) | 2010-03-31 |
| JP2010530403A (ja) | 2010-09-09 |
| DK2167095T3 (da) | 2019-07-29 |
| SI2167095T1 (sl) | 2019-09-30 |
| CA2690746C (en) | 2018-01-02 |
| AU2008265045A1 (en) | 2008-12-24 |
| CN101820884B (zh) | 2013-08-28 |
| PL2167095T3 (pl) | 2019-11-29 |
| WO2008155533A2 (en) | 2008-12-24 |
| JP5725605B2 (ja) | 2015-05-27 |
| EP2167095B1 (en) | 2019-05-29 |
| BRPI0813670A2 (pt) | 2014-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2004155T1 (en) | Inhibitors of protein aggregation | |
| EP3529315B1 (en) | Near infrared (nir) dye cancer drug conjugated to a statin | |
| TWI798470B (zh) | 作為神經激肽－１受體拮抗劑的化合物及其用途 | |
| ES2701089T3 (es) | Uso terapéutico de las diaminofenotiazinas | |
| Blandizzi et al. | Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers | |
| EP3684772B1 (en) | Cyclic iminopyrimidine derivatives as kinase inhibitors | |
| AU2012274160B2 (en) | Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo- N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| ES2632471T3 (es) | Novedosa sal de abexinostat, forma cristalina asociada, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| Su et al. | The development of bis (hydroxymethyl) pyrrole analogs as bifunctional DNA cross-linking agents and their chemotherapeutic potential | |
| CN101801942A (zh) | 杂环化合物和作为抗癌剂的用途 | |
| JP2010530403A5 (enExample) | ||
| EP2586780A4 (en) | 2-ARYL-IMIDAZO- [1,2-A] -PYRIDINE-3-ACETAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | |
| HRP20220446T1 (hr) | Lijekovi inhibitora membranskog antigena specifičnog za prostatu (psma) | |
| JP2022184965A (ja) | ヒストン脱アセチル化酵素阻害剤及びエポチロンを含む医薬品組み合わせならびにその使用方法 | |
| HRP20181027T1 (hr) | Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a | |
| EP1467994A1 (de) | Pteridinderivate, verfahren zu deren herstellung und ihre verwendung | |
| JP2002532503A5 (enExample) | ||
| TW202114664A (zh) | Ｂｃｌ－２／Ｂｃｌ－ｘＬ抑制劑與化療藥的組合產品及其在預防和／或治療疾病中的用途 | |
| JP2014514288A5 (enExample) | ||
| JP5733839B2 (ja) | 神経変性疾患治療薬 | |
| Basavarajaiah et al. | Pharmacological Activities of Some 5-Substituted-3-phenyl-Nβ-(substituted-2-oxo-2H-pyrano [2, 3-b] quinoline-3-carbonyl)-1H-indole-2-carboxyhydrazides | |
| ME02351B (me) | Derivati 2 -oxo- 1-imidazolidinil imidazotiadiazol | |
| ES2847229T3 (es) | Compuestos intermedios utilizables en la síntesis de (-)-huperzina y proceso para obtener uno de estos compuestos intermedios | |
| CN105813643A (zh) | 利用含有噻吩并三唑二氮杂*化合物的药物制剂治疗非小细胞肺癌的方法 | |
| ES3012496T3 (en) | Synthesis of a thiosulfonic acid by a step of periodate mediated oxidative coupling of a thiosulfonic acid with an aniline |